עברית

NeuroKaire: How We Told a Story About Depression Without Selling a Cure

NeuroKaire developed a blood test that grows a patient’s own neurons in the lab and checks which antidepressant works on them. It’s a remarkable story, and a dangerous one to tell badly. One overexcited headline and the whole thing looks like a miracle pill. Here is how we thought about it, and what came out of it

18→2months to the right drug, per the company
9major outlets
$25Mraised before the campaign
3languages: Hebrew, English, French

Where it started

When we met founders Dr. Talia Cohen Solal and Dr. Daphna Laifenfeld in September 2025, they were days away from launching BrightKaire. The test had just received approval from CMS, the US federal body behind Medicare. That gave us a news hook. It also raised the stakes: this was going to reach people who are suffering right now

The strategic question

THE QUESTIONHow do you get a test about depression into the business press, the tech press and the health press, without overpromising to patients and without losing the scientists’ credibility?

The decisions we made, and why

Lead with the waiting, not the technology

Anyone who has been treated for depression knows the months of trying one drug after another. We built the launch around that number: finding the right medication can take up to 18 months, and the company says its test can shorten it to about eight weeks. Readers understand time before they understand neurons

Put the scientists in front, not the product

Two women scientists who met through LinkedIn and built a company out of a Columbia postdoc are a story in themselves. We kept the founders as the voice of the company, in interviews and op-eds, so the coverage stayed about science and people, not about a product for sale

Use partnerships as proof

Each new partner did a job a press release can’t do alone: the Compass Pathways research collaboration, the appointment of Dr. Joshua Gordon, former head of the US National Institute of Mental Health, and a partnership with Buzzy on continuous monitoring. Every one of them told reporters that serious people were betting on this

Find the audiences others miss

On i24 we prepared for an English-language business show, and noticed that French-speaking viewers in Israel reacted strongly. For International Women’s Day we offered a different angle: a CEO who is a mother of four, in a field where women suffer from depression at higher rates than men

What it looked like in practice

Sep 2025BrightKaire launch

A Hebrew release under embargo for 9 September at 16:00, built around the waiting time and the CMS approval

Oct 2025The partners

Compass Pathways in Globes, and the appointment of Dr. Joshua Gordon to the advisory board

Dec 2025 to Feb 2026The founders’ voice

Op-eds on Ynetnews, a Geekonomy episode, and a live interview on i24 we prepared the founders for

Jan 2026From test to treatment journey

The Buzzy partnership, framed as a full journey: accurate diagnosis first, then monitoring how the patient actually responds

Want results like these for your company?

Every story here started with one conversation about the business goal. Leave your details and we will call you back

Something went wrong. Please call us or try again

Where it ran

TheMarkerCalcalistCTechGlobesYnetnewsBizportalGeekonomyi24NEWS

What came out of it

A complex biotech story ran in the Hebrew business press, the English-language Israeli tech press and on TV, with the founders as its face. Just as important is what didn’t happen: no headline promised a cure

What you can take from this

  • In health, the most powerful number is usually time, not accuracy
  • Partnerships and appointments are proof, so time them as news
  • The founder is the most credible spokesperson a medical company has
  • A cautious headline is better than a viral one you will regret

More client stories →

Want us to think this way about your company? Tell us where you stand and we’ll come back with a first idea

Let’s talk